TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
TransCode Therapeutics (NASDAQ: RNAZ) has completed initial dosing of the first cohort in its Phase 1a dose-escalation clinical trial for TTX-MC138, an antisense oligonucleotide designed to inhibit microRNA-10b, a driver of metastasis in multiple cancers. Key points:
- All patients in the cohort received their first dose and remain on study for continued treatment
- No significant safety or dose limiting toxicities reported
- TTX-MC138 uses TransCode's proprietary TTX delivery system
- TransCode is the only company with an ongoing US clinical trial targeting microRNA in cancer
- The trial's progress coincides with the 2024 Nobel Prize in Physiology and Medicine recognizing microRNA technology
The company views the rapid enrollment and absence of dose limiting toxicities as encouraging signs for the continued assessment of TTX-MC138's safety and tolerability.
TransCode Therapeutics (NASDAQ: RNAZ) ha completato la somministrazione iniziale del primo gruppo nel suo studio clinico di fase 1a con un aumento della dose per TTX-MC138, un oligonucleotide antisenso progettato per inibire microRNA-10b, un fattore chiave della metastasi in diversi tipi di cancro. Punti chiave:
- Tutti i pazienti del gruppo hanno ricevuto la loro prima dose e continuano a partecipare allo studio per il trattamento prolungato
- Non sono stati segnalati tossicità significative o limitazioni di dose
- TTX-MC138 utilizza il sistema di somministrazione proprietario TTX di TransCode
- TransCode è l'unica azienda con uno studio clinico attivo negli Stati Uniti che mira a microRNA nel cancro
- Il progresso dello studio coincide con il riconoscimento della tecnologia microRNA da parte del Premio Nobel 2024 in Fisiologia e Medicina
L'azienda considera l'arruolamento rapido e l'assenza di tossicità limitanti della dose come segnali incoraggianti per la continua valutazione della sicurezza e della tollerabilità di TTX-MC138.
TransCode Therapeutics (NASDAQ: RNAZ) ha completado la dosificación inicial de la primera cohorte en su ensayo clínico de fase 1a de escalado de dosis para TTX-MC138, un oligonucleótido antisenso diseñado para inhibir microRNA-10b, un impulsor de metástasis en múltiples cánceres. Puntos clave:
- Todos los pacientes en la cohorte recibieron su primera dosis y permanecen en el estudio para tratamiento continuo
- No se han reportado toxicidades limitantes de dosis ni problemas de seguridad significativos
- TTX-MC138 utiliza el sistema de entrega propietario TTX de TransCode
- TransCode es la única empresa con un ensayo clínico en EE. UU. dirigido a microRNA en cáncer
- El progreso del ensayo coincide con la entrega del Premio Nobel de Fisiología y Medicina 2024 que reconoce la tecnología microRNA
La empresa considera que la rápida inscripción y la ausencia de toxicidades limitantes de dosis son señales alentadoras para la continua evaluación de la seguridad y tolerabilidad de TTX-MC138.
TransCode Therapeutics (NASDAQ: RNAZ)는 TTX-MC138에 대한 1단계 임상 시험 첫 번째 군의 초기 투약을 완료했습니다. 이 약물은 microRNA-10b를 억제하기 위해 설계된 안티센스 올리고뉴클레오타이드로, 여러 암에서 전이를 유도하는 역할을 합니다. 주요 사항:
- 모든 군의 환자들이 첫 번째 투약을 받았으며 지속적인 치료를 위해 연구에 남아 있습니다
- 중요한 안전성 문제나 용량 제한 독성은 보고되지 않았습니다
- TTX-MC138은 TransCode의 독점 TTX 전달 시스템을 사용합니다
- TransCode는 암에서 microRNA를 타겟으로 한 미국 임상 시험을 진행하고 있는 유일한 회사입니다
- 이번 시험의 진행은 2024년 노벨 생리학 및 의학상이 microRNA 기술을 인정하는 것과 일치합니다
회사는 신속한 모집과 용량 제한 독성이 없음을 TTX-MC138의 안전성과 내약성을 지속적으로 평가하기 위한 고무적인 신호로 보고 있습니다.
TransCode Therapeutics (NASDAQ: RNAZ) a achevé la première administration de la première cohorte dans son essai clinique de phase 1a d'escalade de dose pour TTX-MC138, un oligonucléotide antisens conçu pour inhiber microRNA-10b, un facteur de métastase dans plusieurs cancers. Points clés :
- Tous les patients de la cohorte ont reçu leur première dose et restent dans l'étude pour un traitement continu
- Aucune toxicité significative ou limitante de dose n'a été signalée
- TTX-MC138 utilise le système de délivrance propriétaire TTX de TransCode
- TransCode est la seule entreprise avec un essai clinique en cours aux États-Unis ciblant les microARN dans le cancer
- Le progrès de l'essai coïncide avec la reconnaissance de la technologie des microARN par le prix Nobel 2024 de physiologie et de médecine
L'entreprise considère le recrutement rapide et l'absence de toxicités limitantes de dose comme des signes encourageants pour l'évaluation continue de la sécurité et de la tolérabilité de TTX-MC138.
TransCode Therapeutics (NASDAQ: RNAZ) hat die initiale Dosierung der ersten Kohorte in seiner Phase 1a Dosis-Eskalationsstudie für TTX-MC138 abgeschlossen, einem Antisense-Oligonukleotid, das entwickelt wurde, um microRNA-10b zu hemmen, einen Treiber der Metastasierung bei mehreren Krebsarten. Wichtige Punkte:
- Alle Patienten in der Kohorte haben ihre erste Dosis erhalten und bleiben im Studienverlauf für eine fortgesetzte Behandlung
- Es wurden keine signifikanten Sicherheitsprobleme oder dosislimitierenden Toxizitäten gemeldet
- TTX-MC138 verwendet das proprietäre TTX-Abgabesystem von TransCode
- TransCode ist das einzige Unternehmen mit einem laufenden klinischen Versuch in den USA, der microRNA bei Krebs anvisiert
- Der Fortschritt der Studie fällt mit der Verleihung des Nobelpreises 2024 für Physiologie und Medizin zusammen, der die Technologie von microRNA anerkennt
Das Unternehmen sieht die schnelle Rekrutierung und das Fehlen dosislimitierender Toxizitäten als ermutigende Zeichen für die fortgesetzte Bewertung der Sicherheit und Verträglichkeit von TTX-MC138.
- Successful completion of initial dosing for the first cohort in Phase 1a clinical trial
- No significant safety or dose limiting toxicities reported
- Rapid enrollment of the first cohort
- TransCode is the only company with an ongoing US clinical trial targeting microRNA in cancer
- Alignment with recent Nobel Prize recognition of microRNA technology
- None.
Insights
The completion of initial dosing for the first cohort in TransCode Therapeutics' Phase 1 clinical trial for TTX-MC138 is a significant milestone. This microRNA-targeted therapy aims to inhibit microRNA-10b, a key driver of metastatic cancer. The absence of significant safety issues or dose-limiting toxicities is encouraging, potentially supporting continued dosing and assessment.
The trial's progress is particularly noteworthy given the recent 2024 Nobel Prize in Physiology and Medicine recognition of microRNA technology. This validates the scientific foundation of TransCode's approach and could increase investor interest in microRNA-based therapies.
However, it's important to note that this is still an early-stage trial and the market cap of
From a financial perspective, this news is positive for TransCode Therapeutics (NASDAQ: RNAZ) but should be viewed cautiously. The successful dosing of the first cohort without safety issues is a de-risking event, potentially increasing the company's value proposition. However, the company's micro-cap status (
Investors should consider:
- Cash runway and burn rate
- Potential for dilutive financing rounds
- Milestone payments or partnerships that could provide non-dilutive funding
The Nobel Prize connection may attract attention, potentially leading to increased trading volume or temporary stock price movements. Long-term value, however, will depend on clinical progress and the company's ability to advance its pipeline cost-effectively. Given the early stage and small size, RNAZ remains a highly speculative investment suited for risk-tolerant investors with a long-term horizon.
- Patients currently remain on study for continued treatment with TTX-MC138
- No significant safety or dose limiting toxicities reported
- TTX-MC138, an antisense oligonucleotide conjugated to TransCode’s proprietary TTX delivery system, is designed to inhibit microRNA-10b, a known driver of metastasis in multiple cancers
- microRNA technology was recognized with the 2024 Nobel Prize in Physiology and Medicine
- TransCode is the only company with an ongoing US clinical trial targeting microRNA in cancer
BOSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has dosed all patients in the first cohort of its Phase 1a dose-escalation clinical trial. The therapeutic candidate being evaluated, TTX-MC138, is TransCode’s lead candidate designed to inhibit microRNA-10b, a microRNA critical to the emergence and progression of metastatic cancer. All patients in the cohort received their first dose of TTX-MC138 and remain on study for continued treatment. No significant safety or dose limiting toxicities have been reported.
“The rapid enrollment of the first cohort is extremely encouraging. The absence of dose limiting toxicities thus far supports continued dosing and assessment of TTX-MC138 for safety and tolerability,” commented Sue Duggan, TransCode’s Senior Vice President of Operations. Duggan added, “We are excited to be in the clinic with TTX-MC138 on the heels of the recent announcement that this year’s Nobel Prize in Physiology and Medicine was awarded to the discoverers of microRNA. Their work informs the understanding of microRNA’s role in gene regulation, which we believe reflects the potential of TTX-MC138.”
About microRNA
MicroRNA is a regulatory molecule naturally occurring in cells that plays crucial roles in development, physiology, and disease. The 2024 Nobel Prize in Physiology and Medicine was awarded to US scientists Dr. Victor Ambros and Dr. Gary Ruvkun for their 1993 discovery of microRNA and its function in controlling the array of proteins that a cell produces and governing how cells in the body function.
About TTX-MC138
TTX-MC138 is a first-in-class therapeutic candidate that targets microRNA-10b, a micro-RNA widely believed to be a driver of metastatic disease. TransCode’s 2023 Phase 0 clinical trial produced evidence of delivery of a radiolabeled version of TTX-MC138 to metastatic lesions and pharmacodynamic activity, even at a microdose of the drug candidate, suggesting a broad therapeutic window for TTX-MC138.
About the Trial
The Phase 1 clinical trial is a multicenter, open-label, dose-escalation and dose-expansion study, designed to generate critical data to support evaluation of the safety and tolerability of TTX-MC138 in patients with a variety of metastatic solid cancers. While not an endpoint, the trial may provide early evidence of clinical activity of TTX-MC138. The trial comprises an initial dose-escalation phase followed by a dose-expansion phase. The primary objective of the dose-escalation phase is to evaluate the safety and tolerability of escalating dose levels of TTX-MC138. In the dose-expansion phase, the safety, tolerability and anti-tumor activity of TTX-MC138 will be further evaluated in certain tumor types selected based on preliminary results from the dose-escalation phase.
Further information is available at www.clinicaltrials.gov NCT Identifier: (NCT06260774).
About TransCode Therapeutics
TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of other first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the timing, conduct and results of the Phase 1 clinical trial, any statement about microRNAs and their involvement in cancer, and statements concerning the therapeutic potential of TransCode’s TTX-MC138. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risks associated with drug discovery and development; the risk that the results of clinical trials will not be consistent with TransCode’s pre-clinical studies or expectations or with results from previous clinical trials; risks associated with the conduct of clinical trials; risks associated with TransCode’s financial condition and its need to obtain additional funding to support its business activities, including TransCode’s ability to continue as a going concern; risks associated with the timing and outcome of TransCode’s planned regulatory submissions; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; risks of competition from other companies developing products for similar uses; risks associated with TransCode’s dependence on third parties; and risks associated with geopolitical events and pandemics, including the COVID-19 coronavirus and military actions. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause TransCode’s actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled “Risk Factors” in TransCode’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as discussions of potential risks, uncertainties and other important factors in any subsequent TransCode filings with the Securities and Exchange Commission. All information in this press release is as of the date of this release; TransCode undertakes no duty to update this information unless required by law.
For more information, please contact:
TransCode Therapeutics, Inc.
Tania Montgomery-Hammon, VP of Business Development
tania.montgomery@transcodetherapeutics.com
FAQ
What is the purpose of TransCode Therapeutics' Phase 1 clinical trial for TTX-MC138?
Has TransCode Therapeutics (RNAZ) reported any safety concerns with TTX-MC138 in the initial dosing?
What is unique about TransCode Therapeutics' (RNAZ) clinical trial with TTX-MC138?